Skip to main content

Table 3 PROGRESS intensive care treatment

From: The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Variable

DrotAA

n = 882

Non-DrotAA

n = 11,610

Total

n = 12,492

P value

IV fluid resuscitation, n (%)

(n = 782)

718 (91.8)

(n = 10,492)

9053 (86.3)

(n = 11,274)

9771 (86.7)

<0.001

Mechanical ventilation, n (%)

(n = 882)

842 (95.5)

(n = 11,609)

9838 (84.7)

(n = 12,491)

10,680 (85.5)

<0.001

Vasopressors, n (%)

(n = 882)

828 (93.9)

(n = 11,608)

9005 (77.6)

(n = 12,490)

9833 (78.7)

<0.001

Nutrition:

    

   Enteral, n (%)

(n = 882)

678 (76.9)

(n = 11,588)

8369 (72.2)

(n = 12,470)

9047 (72.6)

0.003

   Parenteral, n (%)

(n = 882)

383 (43.4)

(n = 11,601)

3726 (32.1)

(n = 12,483)

4109 (32.9)

<0.001

Heparin:

    

   Low molecular weight

(n = 871)

418 (48.0)

(n = 11,586)

3879 (33.5)

(n = 12,457)

4297 (34.5)

<0.001

   Unfractionated

(n = 868)

345 (39.8)

(n = 11,601)

4628 (39.9)

(n = 12,469)

4973 (39.9)

0.932

Steroids:

    

   Low dose

(n = 878)

499 (56.8)

(n = 11,559)

3994 (34.6)

(n = 12,437)

4493 (36.1)

<0.001

   High dose

(n = 880)

156 (17.7)

(n = 11,600)

1397 (12.0)

(n = 12,480)

1553 (12.4)

<0.001

Mechanical VTE prophylaxis

(n = 765)

295 (38.6)

(n = 10,371)

2407 (23.2)

(n = 11,136)

2702 (24.3)

<0.001

Renal replacement therapy

(n = 876)

283 (32.3)

(n = 11,598)

2383 (20.6)

(n = 12,474)

2666 (21.4)

<0.001

Platelet transfusion

(n = 780)

178 (22.8)

(n = 10,483)

1677 (16.0)

(n = 11,263)

1855 (16.5)

<0.001

  1. DrotAA = drotrecogin alfa (activated); PROGRESS = Promoting Global Research Excellence in Severe Sepsis; VTE = venous thromboembolism.
Back to article page

Critical Care

ISSN: 1364-8535